Harbin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and trade of pharmaceuticals in China and internationally. The company operates through seven segments: Antibiotics, Small-Molecular Drug Preparations, OTC and Healthcare Products, Modern Chinese Medicines, Biopharmaceuticals, Animal Vaccines, and Medicine Circulations. It offers a series of penicillin and cephalosporin products, as well as intermediates. The company's lead products include Shuang Huanglian freeze-dried injection; Danshen freeze-dried injection; Shuang Huanglian powder for injection; roxithromycin dispersible tablets; belladonna, sulfamethoxazole, and trimerhoprim tablets; pediatric paracetamol, atificial cow-bezoar, and chlorphenamine maleate granules; Shuanghuanglian oral liquid; and ceftriaxone sodium for injection. Its lead products also comprise amoxicillin capsules, cefotiam hydrochloride for injection, panax ginseng extract, cefepime hydrochloride for injection, cefoperazone sodium for injection, and amoxicillin sodium and clavulanate potassium for injection; cefuroxime sodium, ceftazidime, cefotaxime sodium, and ceftriaxone sodium for injections; and ampicillin capsules. In addition, the company offers medical protective and disposable surgical masks, medical disposable protective gowns, and isolation gowns. It offers its products under the Hongyan Yaopin, Guangwei, Renmin Tongtai, Hayao Shengwu, Baohulu, Manshanhong, Hutong, Hayaoliu, Gaizhonggai, Sanchine, Shiyitang, and Hayao brands. The company is based in Harbin, China.

Harbin Pharmaceutical Group Co., Ltd.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc.

哈药集团股份有限公司 is a large enterprise group that integrates pharmaceutical manufacturing, trade, and research.

Metric
Company Name	Harbin Pharmaceutical Group Co., Ltd.	CanSino Biologics Inc.
Symbol	600.66K	6.18K
MSH ID	COM:HAYAO	COM:CANSINOTECH
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Drug Manufacturers - Specialty & Generic	Drug Manufacturers - Specialty & Generic
Country	CN	CN
Stage
Employee Count	9.85K	1.49K
Website	hayao.com	cansinotech.com
LinkedIn	%E5%93%88%E8%8D%AF%E9%9B%86%E5%9B%A2%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8	cansino-biotechnology-inc.
Founders

Metric
Market Cap	1.03B	833.96M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.11B	49.12M
Revenue (LTM)
Revenue (NTM)
Gross Profit	518.12M	-61.04M
EBITDA	126.34M	-203.86M
Operating Income	84.47M	-236.92M
Net Income	54.37M	-203.94M
EPS	0.02	-0.83
Diluted EPS	0.02	-0.83
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.28	0.14
Operating Profit Margin	0.06	-0.86
EBITDA Margin	0.06	-4.15
Net Profit Margin	0.04	-1.42
Return on Equity	0.13	-0.16
Return on Assets	0.04	-0.11
Return on Capital Employed	0.15	-0.08

6006

COM:HAYAO

哈药集团股份有限公司

Last Close

3.68

25/11 07:00

Market Cap

7.48B

Beta: -

Volume Today

27.67M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	10.67
P/B Ratio	1.38
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.63	20.35
EV Multiple	10.98	-3.00

Metric
Days Sales Outstanding	132.20	485.87
Days Payables Outstanding	123.38	170.20
Days Inventory Outstanding	62.24	251.49
Operating Cycle	192.47	815.83
Cash Conversion Cycle	109.32	770.86
Asset Turnover	1.11	0.07

Metric
Operating Cash Flow	130.70M	-124.92M
Free Cash Flow	118.80M	-208.89M
Cash Flow to Debt	0.52	-0.12
Operating Cash Flow/Sales	0.07	-0.43
Free Cash Flow Yield	0.16	-0.25

Metric
Cash & Equivalents	420.95M	388.10M
Accounts Receivable	-12.99M	36.58M
Inventory	264.67M	48.53M
Goodwill	5.38M
Debt to Capitalization	0.41	0.34
Debt to Assets	0.14	0.21
Current Ratio	1.25	2.24
Quick Ratio	1.08	2.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.01	1.04
SG&A to Revenue	0.01	0.34